AML is a heterogeneous disease characterized by extensive molecular changes that affect clinical outcomes and provide potential targets for drug development [1, 2], such as targeting the FLT3 mutations in AML [29]. The gene discussed is FLT3; the disease is acute myeloid leukemia.